Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Pharmacology of Infectious Diseases
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1467086
This article is part of the Research Topic Alternatives to Conventional Antibiotics: Biologics, Chemical Modulators and Microbiome Manipulation View all articles

Antibiotics-Free Compounds for Managing Carbapenem-Resistant Bacteria; a narrative review

Provisionally accepted
  • 1 Arak University of Medical Sciences, Arak, Iran
  • 2 Hamadan University of Medical Sciences, Hamedan, Hamadan, Iran

The final, formatted version of the article will be published soon.

    Carbapenem-resistant (CR) Gram-negative bacteria have become a significant public health problem in the last decade. In recent years, the prevalence of CR bacteria has increased. The resistance to carbapenems could result from different mechanisms such as loss of porin, penicillin-binding protein alteration, carbapenemase, efflux pump, and biofilm community. Additionally, genetic variations like insertion, deletion, mutation, and post-transcriptional modification of corresponding coding genes could decrease the susceptibility of bacteria to carbapenems. In this regard, scientists are looking for new approaches to inhibit CR bacteria. Using bacteriophages, natural products, nanoparticles, disulfiram, N-acetylcysteine, and antimicrobial peptides showed promising inhibitory effects against CR bacteria. Additionally, the mentioned compounds could destroy the biofilm community of CR bacteria. Using them in combination with conventional antibiotics increases the efficacy of antibiotics, decreases their dosage and toxicity, and resensitizes CR bacteria to antibiotics. Therefore, in the present review article, we have discussed different aspects of non-antibiotic approaches for managing and inhibiting the CR bacteria and various methods and procedures used as an alternative for carbapenems against these bacteria.

    Keywords: Carbapenems-resistant, natural compounds, Bacteriophages, nanoparticle, N-acetylcysteine, antimicrobial peptides

    Received: 19 Jul 2024; Accepted: 04 Sep 2024.

    Copyright: © 2024 Shariati, Kashi, Chegini and Hosseini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Aref Shariati, Arak University of Medical Sciences, Arak, Iran
    Seyed M. Hosseini, Hamadan University of Medical Sciences, Hamedan, Hamadan, Iran

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.